Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective randomised controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE

Trial Profile

A prospective randomised controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE

Completed
Phase of Trial: Phase II/III

Latest Information Update: 25 Mar 2019

At a glance

  • Drugs Rivaroxaban (Primary) ; Warfarin
  • Indications Antiphospholipid syndrome; Thrombosis; Venous thromboembolism
  • Focus Pharmacodynamics
  • Acronyms RAPS
  • Most Recent Events

    • 22 Mar 2019 Status changed from active, no longer recruiting to completed.
    • 31 Aug 2018 Biomarkers information updated
    • 19 Aug 2016 Results assessing complement activation markers, published in the Journal of Thrombosis and Haemostasis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top